Ask AI
ProCE Banner Activity

Understanding ROS1-Positive NSCLC: Biology, Biomarker Testing, and Evolving Clinical Evidence

Slideset

These downloadable slides review the biology and clinical significance of ROS1 rearrangements in non-small-cell lung cancer (NSCLC), with an emphasis on optimizing biomarker detection and translating molecular findings into treatment selection. The content compares available testing approaches, including FISH, immunohistochemistry, plasma-based testing, and DNA- and RNA-based next-generation sequencing, and highlights practical considerations for comprehensive molecular profiling and accurate identification of ROS1 fusions. It also examines guideline-based treatment recommendations and clinical efficacy and safety data for established and emerging ROS1-targeted therapies, including crizotinib, entrectinib, repotrectinib, taletrectinib, and zidesamtinib, with attention to systemic and intracranial activity, acquired resistance such as the ROS1 G2032R mutation, and outcomes after prior ROS1 TKI exposure. By integrating molecular testing strategies, evolving clinical evidence, resistance patterns, CNS efficacy, toxicity, and patient- and disease-specific factors, this activity is designed to support individualized sequencing and selection of ROS1-directed therapy in clinical practice.

Released: August 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Nuvation Bio Inc.

Nuvation Bio Inc.

Target Audience

Oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other HCPs caring for patients with non-small-cell lung cancer or thoracic cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement appropriate molecular testing strategies to accurately identify patients with NSCLC harboring ROS1 rearrangements and other actionable oncogenic drivers

  • Select evidence-based targeted therapies for patients with ROS1-positive NSCLC based on biomarker findings, disease characteristics, current clinical data, and established treatment guidelines

  • Develop and optimize multidisciplinary workflows that support timely comprehensive biomarker testing and accurate detection of ROS1 rearrangements in patients with NSCLC

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content, and drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.